A Combination of Sulindac and Antimicrobial Eradication of *H. pylori* Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice

Chung-Wei Lee[1], **Barry Rickman**[1], **Arlin B. Rogers**[1], **Sureshkumar Muthupalani**[1], **Shigeo Takaishi**[2], **Peiying Yang**[3], **Timothy C. Wang**[2], and **James G. Fox**[1]

[1]Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA

[2]Division of Digestive and Liver Disease, Department of Medicine, Columbia University, 630 W. 168th Street, Box 83, New York City, NY 10032, USA

[3]Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

Abstract

Helicobacter pylori infection causes severe dysplasia manifested as gastrointestinal intraepithelial neoplasia (GIN) after 28 weeks post *H. pylori* infection (WPI) in cancer-prone, hypergastrinemic male INS-GAS mice. We examined the efficacy of the NSAID sulindac (400 ppm in drinking water) alone, the CCK2/gastrin receptor antagonist YM022 (45 mg/kg/week) alone, and sulindac or YM022 combined with *H. pylori* eradication therapy to prevent *H. pylori*-associated gastric cancer in male INS-GAS mice. Treatments started at 22 WPI, and mice were euthanized at 28 WPI. In uninfected mice, all treatments significantly delayed development of spontaneous GIN (p<0.05). In *H. pylori*-infected mice, sulindac alone or YM022 alone had no protective effect on *H. pylori*-associated GIN. Importantly, sulindac exacerbated the severity of *H. pylori*-associated gastritis despite decreased gastric PEG$_2$ levels. However, sulindac combined with *H. pylori* antimicrobial eradication reduced the incidence of GIN (p<0.05), whereas YM022 combined with antimicrobial eradication did not reduce GIN. In infected mice, sulindac or YM022 treatment did not alter gastric expression of the proinflammatory cytokines *Ifn*-γ and *Tnf*-α and mucosal cell proliferation. Sulindac or YM022 combined with antimicrobial eradication down-regulated mRNA levels of *Ifn*γ and *Tnf*α, and mucosal cell proliferation (p<0.05). We conclude that sulindac enhances *H. pylori* gastritis and may promote inflammation-mediated gastric carcinogenesis. The combination of sulindac and antimicrobial *H. pylori* eradication was beneficial for reducing proinflammatory cytokine mRNA in the stomach and preventing progression from severe dysplasia to gastric cancer in *H. pylori*-infected INS-GAS mice.

Keywords

sunlindac; gastric cancer; antimicrobials; *Helicobacter pylori*; gastrin receptor antagonist (YM022)

Corresponding author: James G. Fox, jgfox@mit.edu, ph 617-253-1757, fax 617-258-5708, Division of Comparative Medicine, Massachusetts Institute of Technology, #16-825, 77 Massachusetts Ave., Cambridge, MA 02139.

Introduction

Based on experimental animal models and epidemiological evidence, *Helicobacter pylori* infection causes persistent chronic gastritis, which in susceptible individuals, may progress to atrophy, intestinal metaplasia, dysplasia, and finally intestinal-type gastric cancer (1-4). *H. pylori* infection resulted in overexpression of type 2 cyclooxygenase (Cox-2) in primary gastric cancer and gastric cancer cell lines of human and mouse gastric epithelial cells (5,6). Double transgenic mice that constitutively expressed Cox-2 and prostaglandin E synthase-1 (*Pges-1*) in gastric epithelial cells had higher levels of prostaglandin E_2 (PGE_2) in the stomach and spontaneously develop macrophage infiltration, metaplasia, and gastric adenocarcinoma. This Cox-2/PGE_2-related gastric cancer was suppressed by a *Cox-2* inhibitor, NS-398 (7), suggesting that *Cox-2*/PGE_2 pathway may contribute to helicobacter-associated gastric carcinogenesis. Recent studies suggested a positive association between hypergastrinemia, *H. pylori* infection, and gastric cancer in humans and mice (8-11). Hypergastrinemia and helicobacter infection synergistically promoted gastric cancer in male transgenic INS-GAS mice overexpressing amidated gastrin (8,9,11). Because decades of *H. pylori* infection are a prerequisite for gastric cancer development in susceptible hosts (1), chemoprevention is one of the promising approaches in gastric cancer prevention.

Since overexpression of Cox-2 and production of PGE_2 are strongly associated with increased proliferation and reduced apoptosis in gastrointestinal epithelial tumor cells (12), non-steroid anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (Cox) activities and production of PGE_2 are among the most widely tested compounds for cancer chemoprevention (13,14). Inhibition of Cox activities decreased cell proliferation in gastric and intestinal cell lines that constitutively expresses Cox-2 (15,16). Animal models demonstrated that the non-selective Cox inhibitor, sulindac, prevents oral-esophageal cancer and colon cancer (17,18). Epidemiological studies also associate consumption of aspirin or other NSAIDs with a reduced risk of colorectal cancer (19) (20) In addition, clinical trials confirmed that sulindac, and the selective Cox-2 inhibitor celecoxib, inhibit the number and growth of adenomatous polyps in patients with familial adenomatous polyposis (21,22). A lower risk of gastric cancer has been associated with NSAIDs in a dose-dependent manner (23). Considering the association between Cox-2/PGE_2 pathway and helicobacter-associated gastric carcinogenesis, NSAIDs have been proposed as candidates for chemoprevention of gastric cancer. However, recent data indicate that suppression of PGE_2 by Cox-2 inhibition enhanced Th1 proinflammatory immune responses in *H. pylori*-infected humans (24,25); this raises the possibility that NSAIDs may increase *H. pylori*-associated gastritis and enhance inflammation-mediated gastric carcinogenesis (2).

It also has been demonstrated that long-term treatment of CCK2/gastrin receptor antagonist YF476 prevented the development of helicobacter-associated gastric cancer in INS-GAS mice (26,27), suggesting that the gastrin signaling pathway provides another potential target for cancer chemoprevention. However, the effect of short-term CCK2/gastrin receptor antagonist treatment has not been analyzed. Long-term treatment of sulindac did not cause tissue injury of gastric mucosa of mice (18) (A. Rustagi personal communication). A recent study demonstrated that gastric PGE_2 in *H. pylori* infection was mainly derived from Cox-1, and the selective Cox-2 inhibitor, rofecoxib, did not suppress PGE_2 production or gastric epithelial proliferation, biomarkers of carcinogenesis (28).

We examined the chemopreventive effects of the non-selective Cox inhibitor sulindac and CCK2/gastrin receptor antagonist YM022 (29), an analogue of YF476 (26), alone or in combination with *H. pylori* antimicrobial eradication during the chronic stage of *H. pylori* infection in male, INS-GAS mice.

Materials and Methods

Mice

Specific pathogen-free (including *Helicobacter* spp.) male INS-GAS mice on a FVB/N background were maintained in an AAALAC accredited facility housed in microisolator cages, and given a commercial rodent diet (Prolab 3000, Richmond, Indiana) and water *ad libitum*. The animal protocol was approved by the MIT Committee on Animal Care.

Experimental design

Fifty-four, 6-8 week old male mice were infected by oral gavage with 0.2 ml of *H. pylori* (SS1 strain) on alternate days for a total of 3 doses (30). The *H. pylori* inoculum was adjusted with PBS to OD_{600}=1.0 (30). *Helicobacter*-uninfected mice were sham-dosed with 0.2 ml of PBS. Antimicrobial therapy used to eradicate *H. pylori* consisted of omeprazole (400 μmol/kg/day, Sigma-Aldrich, St. Louis, MO), metronidazole (14.2 mg/kg/day, Sigma-Aldrich), and clarithromycin (7.15 mg/kg/day, Abbott Chicago, IL) twice a day for 7 days. This regimen has been used successfully in eradicating *H. pylori* from experimentally infected mice (31,32). Antimicrobial *H. pylori* therapy was administered at 22 weeks post *H. pylori* infection (WPI). Sulindac was dissolved in buffer (Na_2HPO_4 4 mM, pH 7.4) at the final concentration of 400 ppm, given *ad libitum*, and changed daily from 22 WPI (18)YM022 was dissolved in polyethylene glycol 300 (Sigma) by stirring for 24 hours at room temperature, and 45 mg/kg was injected subcutaneously once a week starting at 22 WPI (27). Mice were euthanized at 28 WPI.

Tissue collection and gastric pH measurement

Mice were fasted overnight (8 - 14 hours) before necropsy. Following CO_2 asphyxiation, blood was immediately collected by cardiac puncture. The stomach was clamped at both esophageocardial and pyloroduodenal junctions. Sterile water (1.5 ml) was injected into the stomach, the stomach was massaged gently, and the pH of the aspirated gastric contents were measured using a pH meter (Orion PerpHecT model 320, Thermo Scientific, Waltham, MA).

Histological analysis

The stomach was incised along the greater curvature. Linear gastric strips from the lesser curvature were fixed in 10% neutral-buffered formalin or 70% ethanol, embedded, cut at 4 μm, and stained with hematoxylin and eosin (H&E). Tissue sections were scored for gastric lesions using previously published criteria by two veterinary pathologists (A.B.R and B.R.) blinded to sample identity (33). A dysplasia score of 3.0 was considered low-grade gastrointestinal intraepithelial neoplasia (GIN). Dysplasia scores equal or higher than 3.5 represented high-grade GIN (34). Ki-67 immunostaining (BD Biosciences, San Diego, CA) was used to measure epithelial proliferation of gastric mucosa. The ratio of Ki-67-positive to total epithelial nuclei in all glands of the proximal corpus was quantified manually to ascertain the Ki-67 labeling index (LI), and results were averaged from 3-4 mice per group.

Confirmation of *H. pylori* eradication by quantitative PCR

A longitudinal strip of gastric tissue from the greater curvature was digested with proteinase K at 55°C overnight followed by DNA extraction with phenol:chloroform:isoamyl alcohol (25:24:1) and ethanol precipitation. *H. pylori* colonization levels in gastric tissue were quantified using 100 ng of genomic DNA by a fluorogenic quantitative PCR assay with urease B primers as previously describedt (35).

Determination of PGE$_2$ in mouse gastric tissues

Approximately 30 to 50 mg of frozen mouse gastric tissue was ground to a fine powder using a liquid-nitrogen-cooled mortar (Fisher Scientific Co., Fair Lawn, NJ). Samples were then transferred to sealed microcentrifuge tubes, and three times the volume of ice-cold PBS buffer containing 0.1% Butylated hydroxytoluene (BHT, Sigma-Aldrich) and 1 mM EDTA (Sigma-Aldrich) were added. The sample was then homogenized by an Ultrasonic Processor (Misonix, Farmingdale, NJ) at 0 °C for 3 minutes. An aliquot (100μl) of homogenate was transferred to a glass tube (13 × 100 mm) and subjected to extraction of prostaglandins using a method previously described (36). The results were expressed as nanograms of PGE$_2$ / mg protein.

Quantitative analysis of mRNA expression

A longitudinal strip of gastric tissue from the anterior wall was harvested and snap-frozen in liquid nitrogen and then stored at -70°C. Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized from 5 μg of total RNA with High Capacity cDNA Archive kit. mRNA levels of *Ifn-*γ, *Tnf-*α, *Il-4*, cycloxygenase 1 (*Cox-1* or ptgs1, ABio), cycloxygenase 2 (*Cox-2* or *Ptgs2*), and glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) were quantified with TaqMan gene expression assays using an ABI Prism Sequence Detection System 7700 (Applied Biosystems, Foster City, CA). mRNA levels of each gene were normalized to the mRNA level of internal control *Gapdh* and compared to the data of uninfected mice using the ΔΔCT method (User Bulletin #2, ABio).

Statistical analysis

Gastric lesion scores and Ki-67 LI for proliferation indices were compared using the Mann-Whitney *U* test. PGE2 levels, expression levels of cytokines, and IgG titers were compared using the student *t* test. Incidences of low-grade and high-grade GIN in the treatment groups were compared to controls by Chi-square test and Fisher's exact *t* test using commercial software (Graphpad Prism 4.0, GraphPad Software, Inc., San Diego, CA). Data were presented as mean +/- standard error.

Results

The effect of chemopreventive therapies on gastric pH in uninfected and *H. pylori*-infected INS-GAS mice

To assess the impact of *H. pylori* infection with or without treatment on the gastric acidity of INS-GAS mice, the pH of gastric aspirate was measured. Untreated, uninfected INS-GAS mice had a gastric pH=4.76+/-2.2. Among *H. pylori*-uninfected mice, gastric pH was reduced by sulindac (pH=3.37+/-0.16, p<0.001), and sulindac and antimicrobial therapy also reduced gastric pH (pH=3.85+/-0.38, p=0.07) (Supplemental Fig. 1). Uninfected mice that received sulindac or sulindac and antimicrobial therapy had comparable gastric pH (p=0.21). In contrast, uninfected mice that received gastrin receptor antagonist YM022 or YM022 and antimicrobial therapy did not alter gastric pH (pH=4.72+/-0.25 and 4.59+/-0.2, respectively).

H. pylori infection and antimicrobial eradication were confirmed by quantitative PCR at necropsy. *H. pylori* was successfully eradicated in all mice (100%) that received antimicrobial therapy at 22 WPI (data not shown). *H. pylori* infection significantly increased the gastric pH in INS-GAS mice (pH=6.28+/-0.12, p<0.001). Among *H. pylori*-infected mice, the gastric pH was reduced by sulindac (pH=4.96+/-0.22) and sulindac and antimicrobial therapy (pH=4.59 +/-0.22) (both p<0.001). *H. pylori*-infected mice that received sulindac or sulindac and antimicrobial therapy had a similar gastric pH (p=0.24). Infected mice that received YM022 had a gastric pH (pH=6.35+/-0.05) comparable to that in untreated, infected mice. However, YM022 and antimicrobial therapy reduced the gastric pH (pH=5.55+/-0.25) in the infected

mice when compared to untreated infected mice (p=0.07) or infected mice that received YM022 (p<0.01).

Sulindac reduces gastric PGE_2 levels in INS-GAS mice

Among *H. pylori*-uninfected mice, sulindac reduced gastric PGE_2 levels (1.09+/-0.27 ng/mg protein) compared to untreated mice (3.03+/-0.59 ng/mg protein, p<0.01) (Fig. 4d). Mice that received sulindac and antimicrobial therapy had lower gastric PGE_2 levels (1.62+/-0.34 ng/mg protein, p=0.09) than untreated mice. Compared to untreated mice, gastric PGE_2 levels were slightly higher in mice that received YM022 (4.33+/-0.71 ng/mg protein, p=0.17) or YM022 and antimicrobial therapy (5.51+/-0.64 ng/mg protein, p<0.05).

H. pylori-infected INS-GAS mice had significantly higher gastric PGE2 levels (9.73+/-0.81 ng/mg protein, p<0.01) when compared to uninfected mice. *H. pylori*-induced gastric PGE_2 levels were inhibited by sulindac (1.29+/-0.48 ng/mg protein, p<0.01) (Fig. 5d). Infected mice receiving sulindac and antimicrobial therapy had significantly lower gastric PGE2 levels (3.47 +/-0.76 ng/mg protein, p<0.01) than untreated, infected mice. YM022 alone reduced gastric PGE2 levels (6.83+/-0.81 ng/mg protein, p<0.05) in *H. pylori*-infected mice, YM022 and antimicrobial therapy did not alter gastric PGE2 levels (9.49+/-0.93 ng/mg protein) when compared to untreated, infected mice.

Sulindac and YM022 inhibit gastric preneoplasia in uninfected INS-GAS mice

H. pylori-uninfected mice developed mild inflammation, epithelial defects, moderate hyperplasia, and severe oxyntic atrophy, intestinal metaplasia, and dysplasia at 34-36 weeks of age (equivalent to 28 WPI) (Fig. 1a and 2). Of the uninfected mice, 66.67% developed low-grade GIN and none developed high-grade GIN. Sulindac treatment started at 28 to 30 weeks of age (equivalent to 22 WPI) significantly reduced premalignant lesions (p<0.01), and incidence of gastric cancer (p<0.05) in uninfected mice (Fig. 2). Low-grade GIN was observed in 10% of the uninfected INS-GAS mice that received sulindac, whereas high-grade GIN was not diagnosed. Sulindac and antimicrobial therapy started at 28 to 30 weeks of age also significantly reduced the severity of premalignant (p<0.05) and malignant lesions (p<0.05) in the uninfected INS-GAS mice. None of the uninfected mice that received the combination of sulindac and antimicrobial therapy developed GIN.

YM022 treatment slightly reduced dysplasia (p=0.079), and the incidence of gastric cancer (p=0.087) in uninfected mice (Fig. 3). Low-grade GIN was diagnosed in 25% of the YM022-treated uninfected mice. YM022 and antimicrobial therapy resulted in less severe dysplasia (p<0.01), and incidence gastric cancer (p<0.01) in the uninfected mice. Additionally, uninfected mice that received YM022 or the combination of YM022 and antimicrobial therapy had comparable severity of gastric lesions (p>0.05).

H. pylori infection promotes gastric carcinogenesis

Helicobacter infection promotes gastric carcinogenesis in mice (9,11). *H. pylori*-infected mice developed more severe gastric inflammation (p=0.065) and epithelial defects (p<0.01) than uninfected mice (Fig. 2). *H. pylori* infection also promoted the development of gastric cancer in all infected mice.

Sulindac increases gastric preneoplasia, while Sulindac and antimicrobial therapy reduces gastric carcinogenesis in *H. pylori*-infected mice

In *H. pylori*-infected mice, sulindac exacerbated the severity of inflammation (p<0.01), oxyntic atrophy (p<0.05), and intestinal metaplasia (p<0.05) (Fig. 1c and 2). Epithelial hyperplasia was reduced by sulindac (p<0.01, data not shown). The severity of dysplasia and the incidence of

gastric cancer were comparable between untreated infected mice and infected mice that received sulindac. All infected mice that received sulindac developed gastric cancer with both low- and high-grade GIN being observed in a *H. pylori*-infected INS-GAS mice (80% and 20%, respectively). Compared to untreated *H. pylori*-infected mice, infected mice that received sulindac and antimicrobial therapy had significantly less severe oxyntic atrophy ($p < 0.05$) and a lower incidence of gastric cancer ($p < 0.05$) (Fig. 1d and 2). Gastric cancer was observed in 64% (38% high and 27% low grade GIN) of the infected mice that received sulindac and antimicrobial therapy. The severity of inflammation, epithelial defects, hyperplasia, intestinal metaplasia, and dysplasia were comparable between the untreated infected mice and infected mice that received sulindac and antimicrobial therapy. Additionally, when compared to *H. pylori*-infected mice that received sulindac, severity of inflammation ($p < 0.001$), oxyntic atrophy ($p < 0.001$), and intestinal metaplasia ($p < 0.01$), and incidence of gastric cancer ($p < 0.01$) were significantly reduced in the infected mice that received the combination therapy.

Compared to untreated *H. pylori*-infected mice, infected mice that received YM022 or a combination of YM022 and antimicrobial therapy showed similar pathology scores (Fig. 3). Gastric cancer developed in all the mice that received YM022 and antimicrobial therapy. Low- and high-grade GIN were observed in 75% and 25% of infected mice that received YM022, and in 44% and 56% of infected mice that received YM022 and antimicrobial therapy, respectively. YM022 or YM022 and antimicrobial therapy had no significant effect on gastric cancer incidence in *H. pylori*-infected mice.

Expression of proinflammatory *Ifn*-γ and *Tnf*-α, *Cox-1*, and *Cox-2* in the stomach is up-regulated by sulindac but down-regulated by sulindac and antimicrobial therapy

Among *H. pylori*-uninfected mice, sulindac significantly up-regulated gastric mRNA levels of *Ifn*-γ and *Tnf*-α ($p < 0.05$) (Fig. 4). mRNA levels of *Ifn*-γ were down-regulated in the mice that received sulindac and antimicrobial therapy compared to uninfected mice that received sulindac ($p < 0.05$), however, the gastric *Ifn*-γ mRNA levels in the mice that received sulindac and antimicrobial therapy were still higher than those in the untreated mice ($p < 0.05$). *H. pylori*-uninfected mice that received combination therapy had similar gastric *Tnf*-α expression, compared to untreated mice or mice that received sulindac. In contrast, *Cox-1* and *Cox-2* expression levels were not altered by sulindac or the combination therapy. Expression levels of proinflammatory cytokines and Cox enzymes were not changed in uninfected mice by YM022 or the combination of YM022 and antimicrobial therapy. Additionally, gastric *Il-4* mRNA levels were not altered by sulindac or YM022, alone or combined with antimicrobial therapy, respectively.

H. pylori infection upregulated gastric mRNA levels of *Ifn*-γ and *Tnf*-α in male INS-GAS mice ($p < 0.01$) (Fig. 5). *H. pylori* infection, however, had no effect on mRNA levels of *Cox-1*, *Cox-2*, and *Il-4* in the stomach of mice. Compared to untreated *H. pylori*-infected mice, infected mice that received sulindac had significantly higher mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-1*, *Cox-2*, and *Il-4* ($p < 0.05$). Infected mice that received sulindac and antimicrobial therapy had reduced mRNA levels of *Ifn*-γ and *Tnf*-α than those in untreated infected INS-GAS mice ($p < 0.05$). *H. pylori*-infected mice that received sulindac and antimicrobial therapy had higher *Cox-1* mRNA levels ($p < 0.001$) and comparable *Cox-2* and *Il-4* mRNA levels when compared to untreated infected mice. Compared to infected mice that received sulindac, infected mice that received sulindac and antimicrobial therapy had down-regulated mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-2*, and *Il-4* ($p < 0.01$). YM022 did not alter gastric mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-1*, *Cox-2*, and *Il-4* in the infected mice (Fig. 5). *H. pylori*-infected INS-GAS mice that received YM022 and antimicrobial therapy had comparable mRNA levels of *Cox-1*, *Cox-2*, and *Il-4*, and significantly lower mRNA levels of *Ifn*-γ and *Tnf*-α when compared to untreated infected mice and infected mice that received YM022 ($p < 0.05$).

Sulindac and antimibrobial therapy decreased Th1-associated, *H. pylori*-specific IgG2a antibody responses

H. pylori infection significantly induced *H. pylori*-specific, Th1-associated IgG2a responses in mice (p<0.001) (Supplemental Fig. 2a). Sulindac treatment did not alter *H. pylori*-infected IgG2a levels in *H. pylori*-infected mice (p=0.09). Infected mice that received sulindac and antimicrobials had *H. pylori*-specific IgG2a levels comparable to untreated infected mice. Additionally, *H. pylori*-specific IgG2a levels in infected mice that received the sulindac and antimicrobial therapy were significantly lower than those in infected mice that received sulindac (p<0.05). In contrast, YM022 alone or YM022 and antimicrobial therapy did not alter *H. pylori*-specific IgG2a levels in the infected mice. *H. pylori* infection also induced *H. pylori*, Th2-associated IgG1 responses in mice (p<0.001) (Supplemental Fig. 2b). Treatment modalities in *H. pylori*-infected mice had no significant effect on *H. pylori*-specific IgG1 levels compared to untreated infected mice.

Gastric mucosal cell proliferation was reduced by a combination of antimicrobial therapy and sulindac or YM022

Proliferating epithelial cells detected by Ki-67 immunohistochemical staining were observed in the isthmus regions of corpus mucosa in uninfected mice (Fig. 6b). In untreated *H. pylori*-infected mice, proliferating cells in the corpus expanded from the isthmus regions to hypertrophic foveolar regions, and the Ki-67 labeling indices (LI) were higher than in uninfected mice (p<0.01) (Fig. 6a). Among *H. pylori*-infected mice, proliferating cells were observed in the hypertrophic foveolar regions of the corpus in those mice receiving sulindac or YM022. The distribution of proliferative cells was mainly in the isthmus region of the corpus mucosa in the infected mice receiving combination of sulindac or YM022 and *H. pylori* eradication. Ki-67 LI positively correlated with severity of gastric pathology and GIN; Ki-67 LI in *H. pylori*-infected mice receiving sulindac or YM022 was similar to untreated, *H. pylori*-infected mice. Infected mice receiving the combination of sulindac or YM022 and *H. pylori* antimicrobial eradication had lower a Ki-67 LI compared to untreated, *H. pylori*-infected mice and infected mice that received sulindac or YM022 (p<0.05, respectively).

Discussion

The role of Cox-2 in promoting cancer is mainly attributed to PGE$_2$ production and its ability to promote cell proliferation, migration, and angiogenesis and inhibit apoptosis (37). NSAIDs prevent some types of gastrointestinal cancer and other solid tumors in humans (37). In epidemiological studies, the use of NSAIDs is generally associated with a lower risk gastric cancer. However, a chemopreventive effect of NSAIDs on the development of gastric cancer among *H. pylori* infected individuals has not been conclusively shown in human clinical trials (36,38). Patients that underwent *H. pylori* eradication therapy, chronic use of celecoxib was associated with a higher regression rate of gastric precancerous intestinal metaplasia (36). However, in patients that had received *H. pylori* eradication therapy, treatment with another selective Cox-2 inhibitor, rofecoxib, for 2 years did not reduce intestinal metaplasia (38). Considering that cancer chemoprevention by NSAIDs is modulated by both Cox-dependent and -independent pathways (39), NSAIDs may have variable efficacy in their abilities to prevent gastric cancer.

Consistent with a role for Cox-2/PGE$_2$ in carcinogenesis, double-transgenic mice expressing *Cox-2* and *Pges-1* in the gastric mucosa overproduce PGE$_2$ and develop gastric hyperplasia, metaplasia, and cancer in the glandular stomach (7). Since *H. pylori* infection up-regulates Cox-2 expression and PGE$_2$ production (5,6), it is reasonable to hypothesize that suppression of PGE$_2$ should prevent *H. pylori*-associated gastric carcinogenesis. However, *H. pylori*-associated gastritis and *Tnf*-α expression are more severe in *Cox-1*$^{-/-}$ or *Cox-2*$^{-/-}$ mice (40) and

in *H. pylori*-infected mice receiving NSAIDs (41). Furthermore, Cox-2 inhibition enhances Th1 immune responses against *H. pylori* (24,25,41). $CD4^+CD25^+$ regulatory T cell (T_{reg}) function dampens *H. pylori*-associated gastritis in C56BL/6 mice (30). PGE_2 enhances the inhibitory function of human T_{reg} cells in vitro (42). Therefore, T_{reg} cell function in the *H. pylori*-infected mice is likely to be compromised by reduced PGE_2 production in sulindac-treated animals. Suppressed Treg function may have also contributed to enhanced *H. pylori*-associated inflammation in the infected mice receiving sulindac alone, suggesting that PGE_2 induced in response to *H. pylori* infection plays a role in dampening gastric inflammation and reducing inflammation-mediated gastric carcinogenesis (2). The benefit of PGE_2 suppression by NSAIDs in suppressing mediators of cancer progression, however, is not significant to counteract the adverse effect of Cox-2 inhibition associated with Th1-predominant inflammation caused by *H. pylori* infection.

As previously described, *H. pylori* infection promoted gastric carcinogenesis in INS-GAS male mice (8,32). Although treatment with sulindac suppressed *H. pylori*-induced gastric PGE_2 levels, sulindac alone did not prevent gastric cancer in chronically infected INS-GAS mice. Moreover, sulindac exacerbated *H. pylori*-induced gastritis and up-regulated expression of proinflammatory cytokines. In contrast, a combination of sulindac and antimicrobial therapy reduced gastric PGE_2 levels and gastric inflammation, and prevented the development of *H. pylori*-associated gastric cancer. These findings suggest that in the presence of *H. pylori* infection, selected NSAIDs enhance Th1-predominant proinflammatory responses to *H. pylori* antigens (24), and may promote the development of inflammation-mediated gastric cancer in a susceptible host with chronic *H. pylori* infection (2). In previous studies suppression of PGE_2 by *Cox-2* inhibitors did not alter Th2-associated *Il-4* expression; instead, the treatment up-regulated mRNA levels of Th1-associated *Il-12* and *Tnf*-α in gastric tissue of *H. pylori*-infected humans (24,25). Sulindac treatment up-regulated gastric *Ifn*-γ and *Tnf*-α as well as *IL-4* mRNA in *H. pylori*-infected mice. Sulindac-mediated up-regulation of Th1 proinflammatory cytokines positively correlated with the severity of *H. pylori*-associated gastric lesions in infected mice. Sulindac up-regulated gastric *Ifn*-γ and *Tnf*-α mRNA levels in *H. pylori*-uninfected INS-GAS mice, even though gastric lesions and gastric cancer risk were reduced. Sulindac also up-regulated *Cox-1* and *Cox-2* mRNA levels in *H. pylori*-infected INS-GAS mice, despite the fact that it reduced gastric PGE_2 levels as a result of its known Cox-inhibitory effects (43). Sulindac is a prodrug that is converted to sulfone and sulindac sulfide, and the sulfide form has been shown to activate PPAR-γ and induce Cox-2 expression (44). The significance of up-regulated mRNA expression of *Cox-1* and *Cox-2* in *H. pylori*-infected mice that received sulindac is not clear and needs further study. The combination of sulindac and *H. pylori* eradication reduced the *H. pylori*-specific IgG2a titers, which were not significantly altered by sulindac treatment.

Sulindac prevented gastrin-driven carcinogenesis in *H. pylori*-uninfected male mice, despite up-regulation of proinflammatory cytokines. Moreover, the combination of sulindac and antimicrobial therapy were more effective in preventing gastric lesions, reducing cell proliferation in gastric mucosa and incidence of gastric cancer in *H. pylori*-uninfected mice whose stomachs are known to be colonized with enteric flora(32). Normal microbiota colonize all regions of the bowel, including the upper gastrointestinal tract of mice (45). Antimicrobial therapy with omeprazole, metronidazole and clarithromycin resulted in dynamic changes of the gastric microbiota in humans (46). These findings in humans and mice suggest that gastric flora other then *H. pylori* contribute to gastric inflammation and cancer (2).

Chemoprevention of helicobacter-associated gastric cancer in INS-GAS mice was previously observed in long-term (6 months) suppression of CCK2/gastrin signaling by treatment with YF476, which was initiated during the acute stage of helicobacter infection (27). We observed that the CCK2/gastrin receptor antagonist, YM022, alone or in combination with antimicrobial

therapy reduced gastric cancer risk in *H. pylori*-uninfected INS-GAS mice. However, the chemopreventive effect of YM022 alone or in combination with antimicrobial therapy was not observed in *H. pylori*-infected INS-GAS mice when the 6-week treatment was initiated during the chronic stage of *H. pylori* infection. YM022 blockade of gastrin signaling (27) was not sufficient to counteract YM022-associated gastric pH elevation which may facilitate overgrowth of certain gastric flora following *H. pylori* eradication therapy (32). These differing results in our current study and the previous report using YF476 might reflect intrinsic differences in the two antagonists, but were more likely due to the different treatment schedules in these two studies. The data, however, are consistent with gastrin playing an important role early, but not later, in the multistep progression to gastric cancer (11).

Gastric proinflammatory cytokines and cell proliferation markers were down-regulated using the combination of YM022 and *H. pylori* eradication in *H. pylori*-infected INS-GAS mice, suggesting that this regimen has chemopreventive potential for gastric cancer. Regression of preneoplastic gastric intestinal metaplasia following *H. pylori* eradication is positively correlated with the interval that patients have been free of *H. pylori* infection (47). This suggests that regression of *H. pylori*-associated gastric lesions and gastric cancer risk may not be observed during the first few years after treatment (48). A longer period of follow-up may be necessary to examine the chemopreventive effect of helicobacter-associated gastric cancer in INS-GAS mice using a combination of YM022 and *H. pylori* eradication.

Our data demonstrate that NSAIDs are an effective treatment modality in preventing of *H. pylori*-associated gastric cancer provided that *H. pylori* is eradicated before NSAIDs treatment is initiated. This study highlights the possible adverse effect of selected NSAIDs in promoting *H. pylori*-associated gastritis and cancer progression in susceptible hosts, despite the fact that PGE_2 suppression by NSAIDs has chemopreventive properties in treatment of colon cancer and other solid tumors (19,20,37). A probable mechanism by which NSAIDs exacerbates *H. pylori*-associated gastritis and gastric cancer is via an enhanced proinflammatory Th1 immune response. Our study is consistent with the Maastricht III Consensus Report which recommends *H. pylori* eradication for the prevention of peptic ulcer and gastric cancer, especially in patients with long-term NSAID usage (49).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Correa P. A human model of gastric carcinogenesis. Cancer research 1988;48:3554–60. [PubMed: 3288329]

2. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. (Invited review). J Clin Invest 2007;117:60–9. [PubMed: 17200707]

3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–5. [PubMed: 6145023]

4. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Schistosomes liverlukes and Helicobacter pylori.: International Association for Research against Cancer. 1994:1–241.

5. Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer research 2001;61:2399–403. [PubMed: 11289104]

6. Kim TI, Lee YC, Lee KH, et al. Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity. Infection and immunity 2001;69:5056–63. [PubMed: 11447186]

7. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. The EMBO journal 2004;23:1669–78. [PubMed: 15014433]

8. Fox JG, Rogers AB, Ihrig M, et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer research 2003;63:942–50. [PubMed: 12615707]

9. Fox JG, Wang TC, Rogers AB, et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology 2003;124:1879–90. [PubMed: 12806621]

10. Mulholland G, Ardill JE, Fillmore D, Chittajallu RS, Fullarton GM, McColl KE. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993;34:757–61. [PubMed: 8314507]

11. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118:36–47. [PubMed: 10611152]

12. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? The American journal of physiology 1996;270:G393–400. [PubMed: 8638704]

13. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. The lancet oncology 2002;3:166–74. [PubMed: 11902503]

14. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. The New England journal of medicine 2000;342:1960–8. [PubMed: 10874065]

15. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. Journal of clinical gastroenterology 1998;27:S47–52. [PubMed: 9872498]

16. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254–9. [PubMed: 9151799]

17. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. The Journal of pathology 1988;156:341–7. [PubMed: 3225717]

18. Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761–9. [PubMed: 12235107]

19. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer research 1988;48:4399–404. [PubMed: 3390835]

20. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376–89. [PubMed: 17339623]

21. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England journal of medicine 2000;342:1946–52. [PubMed: 10874062]

22. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635–9. [PubMed: 1650315]

23. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute 2003;95:1784–91. [PubMed: 14652240]

24. Meyer F, Ramanujam KS, Gobert AP, James SP, Wilson KT. Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori. J Immunol 2003;171:3913–7. [PubMed: 14530307]

25. Pellicano AIM, Leone I, Larussa T, Luzza F. Enhanced activation of cyclooxygenase-2 downregulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa. Helicobacter 2007:193–9. [PubMed: 17492998]

26. Semple G, Ryder H, Rooker DP, et al. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1, 4-benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. Journal of medicinal chemistry 1997;40:331–41. [PubMed: 9022799]

27. Takaishi S, Cui G, Frederick DM, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005;128:1965–83. [PubMed: 15940630]

28. Scheiman JM, Greenson JK, Lee J, Cryer B. Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention. Alimentary pharmacology & therapeutics 2003;17:1535–43. [PubMed: 12823157]

29. Nishida A, Miyata K, Tsutsumi R, et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. The Journal of pharmacology and experimental therapeutics 1994;269:725–31. [PubMed: 7910212]

30. Lee CW, Rao VP, Rogers AB, et al. Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2-/- mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. Infection and immunity 2007;75:2699–707. [PubMed: 17353283]

31. van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrobial agents and chemotherapy 2003;47:2249–55. [PubMed: 12821476]

32. Lee CW, Rickman B, Rogers AB, Ge Z, Wang TC, Fox JG. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer research 2008;68:3540–8. [PubMed: 18441088]

33. Rogers AB, Taylor NS, Whary MT, Stefanich ED, Wang TC, Fox JG. Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer research 2005;65:10709–15. [PubMed: 16322215]

34. Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124:762–77. [PubMed: 12612914]

35. Maurer KJ, Rogers AB, Ge Z, Wiese AJ, Carey MC, Fox JG. Helicobacter pylori and cholesterol gallstone formation in C57L/J mice: a prospective study. American journal of physiology 2006;290:G175–82. [PubMed: 16109843]

36. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Alimentary pharmacology & therapeutics 2007;25:455–61. [PubMed: 17270001]

37. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 2005;69:28–32. [PubMed: 16210874]

38. Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006;12:4766–72. [PubMed: 16899628]

39. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006;98:736–47. [PubMed: 16757698]

40. Li GQ, Xia HH, Chen MH, et al. Effects of cyclooxygenase-1 and -2 gene disruption on Helicobacter pylori-induced gastric inflammation. The Journal of infectious diseases 2006;193:1037–46. [PubMed: 16518767]

41. Tanigawa T, Watanabe T, Hamaguchi M, et al. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2. American journal of physiology 2004;286:G148–56. [PubMed: 12958020]

42. Baratelli F, Lin Y, Zhu L, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005;175:1483–90. [PubMed: 16034085]

43. Felts AS, Ji C, Stafford JB, et al. Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology. ACS chemical biology 2007;2:479–83. [PubMed: 17602619]

44. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274:8328–34. [PubMed: 10075740]

45. Sarma-Rupavtarm RB, Ge Z, Schauer DB, Fox JG, Polz MF. Spatial distribution and stability of the eight microbial species of the altered schaedler flora in the mouse gastrointestinal tract. Applied and environmental microbiology 2004;70:2791–800. [PubMed: 15128534]

46. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. The Journal of antimicrobial chemotherapy 1999;44:629–40. [PubMed: 10552979]

47. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536–40. [PubMed: 15985559]

48. Mera R, Fontham ET, Bravo LE, et al. Re: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute 2006;98:1426. [PubMed: 17018791]

49. Maltertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772–81. [PubMed: 17170018]

Figure 1.
Gastric histology in mice. At 32-34 weeks old, uninfected male mice exhibited spontaneous gastric epithelial dysplasia with inflammation (a). *H. pylori* infection significantly increased inflammation, oxyntic atrophy, foveolar hyperplasia, and dysplasia in the corpus of age-matched male mice at 28 (WPI) (b). Sulindac treatment exacerbated inflammation but not hyperplasia or dysplasia in *H. pylori*-infected mice (c). *H. pylori* antimicrobial therapy and sulindac significantly reduced inflammation, oxyntic atrophy, foveolar hyperplasia, and dysplasia (d). Tissues were stained with H&E; bar = 400 μM.

Figure. 2.
Gastric histological scores in sulindac groups; inflammation (a), atrophy (b), dysplasia (c), and GIN (d). Sulindac and a combination of sulindac and antimicrobial therapy reduced incidence of both low-grade and high-grade GIN in *H. pylori*-uninfected (p<0.05 and p<0.001, respectively), whereas the combination of sulindac and *H. pylori* eradication reduced gastric cancer incidence in *H. pylori*-infected mice (p<0.05). (*, p<0.05; **, p<0.01; ***, p<0.001).

a

b

c

d

Figure 3.
Gastric histological scores in YM022 groups; inflammation (a), atrophy (b), dysplasia (c), and GIN (d). YM022 or a combination of YM022 and antimicrobial therapy had no effect on the incidence of gastric cancer in *H. pylori*-uninfected or –infected mice (p<0.05). (*, p<0.05; **, p<0.01; ***, p<0.001).

Figure 4.
mRNA expression levels of Th1 cytokines *Ifn*-γ and *Tnf*-α (a), *Cox-1* and *Cox-2* (b), Th2 cytokine *Il-4* (c), and gastric PGE$_2$ levels in *H. pylori*-uninfected mice. Data are presented as fold change relative to untreated, uninfected mice. Sulindac significantly up-regulated gastric *Ifn*-γ and *Tnf*-α (a) mRNA levels (p<0.01 and <0.05, respectively). *Ifn*-γ mRNA levels in mice receiving sulindac and antimicrobial (eradication) were lower than those in mice receiving sulindac (p<0.05), but were higher than untreated mice (p<0.05). *Tnf*-α mRNA levels in mice receiving sulindac and antimicrobial therapy were comparable to untreated mice or mice receiving sulindac. In contrast, YM022 or the combination of YM022 and antimicrobial therapy had no effect on gastric expression of *Ifn*-γ and *Tnf*-α. Gastric expression of *Cox-1*, *Cox-2* (b), or *Il-4* (c) was not influenced by sulindac or YM022 alone or in combination with

antimicrobial therapy. Gastric PGE_2 levels (d) were lower in mice receiving sulindac alone ($p < 0.01$) and a combination of sulindac and antimicrobial therapy ($p = 0.09$), but higher in mice receiving a combination of YM022 and antimicrobial therapy ($p < 0.05$). (*, $p < 0.05$; **, $p < 0.01$ when compared to untreated, uninfected mice or comparison as indicated).

Figure 5.
mRNA expression levels of Th1 cytokines *Ifn*-γ and *Tnf*-α (a), *Cox-1* and *Cox-2* (b), Th2 cytokines *Il-4* (c), and gastric PGE$_2$ levels in *H. pylori*-infected mice. Data are presented as fold changes relative to untreated, uninfected mice. White bars, uninfected INS-GAS mice; black bars, *H. pylori*-infected mice. *H. pylori* infection significantly up-regulated gastric expression of *Ifn*-γ and *Tnf*-α (a) (both $p<0.01$), but did not alter mRNA levels of *Cox-1*, *Cox-2* (b), and *Il-4* (c). mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-1*, *Cox-2*, and *Il-4* were higher in infected mice that received sulindac than untreated, infected mice ($p<0.05$), whereas mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-2*, and *Il-4* were suppressed in infected mice receiving a combination of sulindac and *H. pylori* eradication than those receiving sulindac ($p<0.01$). YM022 treatment did not alter mRNA levels of *Ifn*-γ, *Tnf*-α, *Cox-1*, *Cox-2*, and *Il-4* in the *H. pylori*-infected mice. Infected mice receiving a combination of YM022 and *H. pylori* eradication had down-regulated

Ifn-γ and *Tnf*-α expression compared to those receiving YM022 ($p < 0.05$ or < 0.01, respectively). Gastric PGE_2 levels (d) were significantly reduced in the mice receiving sulindac, a combination of sulindac and eradication therapy ($p < 0.01$) or YM022 ($p < 0.05$). (Compared to untreated, uninfected mice or comparison between indicated groups: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. Compared to untreated, *H. pylori*-infected mice: #, $p < 0.05$).

Figure 6.
Cell proliferation in gastric mucosa; Ki-67 labeling indices (LI) (b), and immunohistochemical staining of Ki-67 (c). Ki-67 LI were compared in corpus mucosa (b). *H. pylori* infection resulted in significantly higher Ki-67 LI in mice (p<0.01). Sulindac or YM022 did not alter *H. pylori*-associated increase of Ki-67 LI in INS-GAS mice. *H. pylori*-infected mice receiving the combination of sulindac or YM022 and *H. pylori* eradication had significantly lower Ki-67 LI compared to untreated, infected mice (both p<0.05) or infected mice that received sulindac or YM022 (p<0.05, respectively). Proliferating cells were positively stained for Ki-67 (c). In helicobacter-uninfected INS-GAS mice, proliferating cells were restricted to the isthmus regions. Zone of proliferating cells expanded from isthmus regions to foveolar regions in the untreated, *H. pylori*-infected mice and infected mice that received sulindac or YM022. Proliferating cells were restricted to the isthmus regions irrespective of the hyperplastic foveolar glands in the infected mice that received a combination of sulindac or YM022 and *H. pylori* eradication. White bar, *H. pylori*-uninfected mice; black bars, *H. pylori*-infected mice; Ki-67 positive cells were stained in brown color. (Compared to uninfected, untreated mice or

comparison between indicated groups: *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$. Compared to infected mice: #, $p<0.05$).